Sigyn Therapeutics (SIGY) Payables (2016 - 2025)
Sigyn Therapeutics (SIGY) posted Payables of $954966.0 for Q3 2025, down 68.56% sequentially from $3.0 million in Q2 2025, and down 60.25% YoY from $2.4 million in Q3 2024.
Sigyn Therapeutics (SIGY) Payables (2016 - 2025) Analysis & Trends
Sigyn Therapeutics has reported Payables for 10 years, with the latest figure at $954966.0 in Q3 2025.
- Quarterly Payables fell 60.25% year-over-year to $954966.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $954966.0 (down 60.25% YoY) and the FY2024 annual result came in at $782590.0, down 66.75% from the prior year.
- Payables retreated to $954966.0 in Q3 2025 per SIGY's latest filing, from $3.0 million in the prior quarter.
- Over five years, Payables peaked at $3.3 million in Q3 2023 and troughed at $622314.0 in Q1 2021.
- A 5-year average of $1.9 million and a median of $2.0 million in 2022 frame the typical range for Payables.
- The sharpest annual moves came in 2021 and 2024: Payables soared 398.69% in 2021, then tumbled 66.75% in 2024.
- Over 5 years, Payables stood at $686876.0 in 2021, then surged by 185.96% to $2.0 million in 2022, then rose by 19.82% to $2.4 million in 2023, then sank by 66.75% to $782590.0 in 2024, then rose by 22.03% to $954966.0 in 2025.
- According to Business Quant data, Payables over the past three periods registered $954966.0, $3.0 million, and $2.9 million for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 108.02 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 428.93 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 35.57 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 622.65 Mn |
| 10 | Sigyn Therapeutics | 48,161.31 | -37,409.69 | - | 3.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 954,966.00 |
| Jun 30, 2025 | 3.04 Mn |
| Mar 31, 2025 | 2.86 Mn |
| Dec 31, 2024 | 782,590.00 |
| Sep 30, 2024 | 2.40 Mn |
| Jun 30, 2024 | 2.27 Mn |
| Mar 31, 2024 | 3.01 Mn |
| Dec 31, 2023 | 2.35 Mn |
| Sep 30, 2023 | 3.31 Mn |
| Jun 30, 2023 | 2.97 Mn |
| Mar 31, 2023 | 2.74 Mn |
| Dec 31, 2022 | 1.96 Mn |
| Sep 30, 2022 | 1.82 Mn |
| Jun 30, 2022 | 1.24 Mn |
| Mar 31, 2022 | 901,067.00 |
| Dec 31, 2021 | 686,876.00 |
| Sep 30, 2021 | 717,617.00 |
| Jun 30, 2021 | 661,963.00 |
| Mar 31, 2021 | 622,314.00 |
| Dec 31, 2020 | 534,673.00 |